Antengene to Present Preclinical Data on Next-Gen ADCs and TCEs at AACR 2026

Bispecific antibody-drug conjugate ATG-125 and T-cell engagers ATG-106 and ATG-112 show promising results in solid tumor models

Mar. 18, 2026 at 12:52am

Got story updates? Submit your updates here. ›

Antengene Corporation, a global biotech company, announced that it will present data from three preclinical studies on its novel cancer therapies at the 2026 American Association for Cancer Research Annual Meeting (AACR 2026). The presentations will feature the bispecific antibody-drug conjugate ATG-125, which targets B7-H3 and PD-L1, as well as two investigational T-cell engagers, ATG-106 (CDH6 x CD3) and ATG-112 (ALPPL2 x CD3), developed using the company's proprietary AnTenGager platform.

Why it matters

Antengene's pipeline of next-generation antibody-based therapies, including bispecific ADCs and T-cell engagers, represents a promising approach to tackling solid tumors by simultaneously modulating immune checkpoints and delivering targeted cytotoxicity. The preclinical data being presented at AACR 2026 highlights the potential of these innovative molecules to provide more effective treatment options for patients with limited therapeutic options.

The details

The ATG-125 bispecific ADC demonstrated strong binding to both B7-H3 and PD-L1, enabling targeted delivery of a cytotoxic payload while also modulating immune checkpoint signaling. In preclinical studies, ATG-125 showed potent target-dependent cytotoxicity and enhanced T-cell activation, leading to marked tumor regression in xenograft models. The T-cell engagers ATG-106 and ATG-112 utilized Antengene's proprietary "2+1" format, featuring bivalent binding to tumor antigens (CDH6 and ALPPL2, respectively) and a sterically masked CD3 arm to restrict T-cell activation to the tumor microenvironment. Both molecules demonstrated potent antigen-dependent T-cell cytotoxicity and robust antitumor activity in preclinical studies, with a favorable cytokine release profile.

  • The AACR 2026 Annual Meeting will take place from April 17 to 22, 2026 in San Diego, California.
  • ATG-125 will be presented on April 21, 2026 from 2:00 PM to 5:00 PM Pacific Time (5:00 AM to 8:00 AM April 22, 2026 Beijing Time).
  • ATG-106 and ATG-112 will be presented on April 20, 2026 from 9:00 AM to 12:00 PM Pacific Time (12:00 AM to 3:00 AM April 21, 2026 Beijing Time).

The players

Antengene Corporation Limited

A global, R&D-driven, commercial-stage biotech company focused on developing first-in-class/best-in-class therapeutics for diseases with significant unmet medical needs.

ATG-125

A novel bispecific antibody-drug conjugate that targets B7-H3 and PD-L1, enabling targeted cytotoxic payload delivery while modulating immune checkpoint signaling.

ATG-106

A novel "2+1" format CDH6-targeted T-cell engager designed to induce potent T-cell dependent cytotoxicity against CDH6-expressing solid tumors.

ATG-112

A novel ALPP/G x CD3 bispecific T-cell engager developed using Antengene's proprietary AnTenGager platform, targeting ALPP/G-positive solid tumors.

AnTenGager™

Antengene's proprietary T-cell engager 2.0 platform featuring "2+1" bivalent binding, steric hindrance masking, and fast on/off CD3 kinetics to minimize cytokine release syndrome and enhance efficacy.

Got photos? Submit your photos here. ›

The takeaway

Antengene's pipeline of innovative antibody-based therapies, including bispecific ADCs and T-cell engagers, showcases the company's commitment to developing next-generation cancer treatments that can more effectively target solid tumors through a combination of immune modulation and targeted cytotoxicity.